Role of cathepsin A and cathepsin C in the regulation of glycosidase activity by Minarowska, Alina et al.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 50, No. 1, 2012
pp. 20–24
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2012
10.5603/FHC.2012.0003
www.fhc.viamedica.pl
REVIEW
Correspondence address: L. Minarowski,
Dept. of Lung Diseases and Tuberculosis,
Medical University of Bialystok, Poland;
tel.: + 48 85 740 95 24, fax: + 48 85 732 41 49;
e-mail: lukasz.minarowski@gmail.com
Role of cathepsin A and cathepsin C
in the regulation of glycosidase activity
Alina Minarowska1, Łukasz Minarowski2, Alicja Karwowska3,
Anna Justyna Milewska4, Marek Gacko5
1Department of Human Anatomy, Medical University of Bialystok, Poland
2Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, Poland
3Department of Epidemiology and Hygiene, Medical University of Bialystok, Poland
4Department of Statistics and Medical Informatics, Medical University of Bialystok, Poland
5Department of Vascular Surgery, Medical University of Bialystok, Poland
Abstract: Increased tissue activity of cathepsin A and cathepsin C can be observed in many pathological condi-
tions. It is associated with an enhanced degradation of glycosaminoglycans, proteoglycans, and glycoproteins,
and results in their decreased tissue content. Cathepsin C releases the glycosidases from complexes formed with
cathepsin A, and reinstates their activity. In this review a current state of knowledge is presented concerning the
regulation of selected glycosidases activity by cathepsin A (EC 3.4.16.1) and C (EC 3.4.14.1). (Folia Histochem-
ica et Cytobiologica 2012, Vol. 50, No. 1, 20–24)
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More than sixty lysosomal hydrolases digest macro-
molecular compounds: proteins, polysaccharides, lip-
ids, and nucleic acids at acidic pH. The lack or defi-
ciency of a certain lysosomal enzyme resulting from
genetic defect or inactivation can lead to the devel-
opment of a storage disease [1]. A disease can be clas-
sified as a lysosomal storage disorder if it fulfils the
following three criteria: 1) the lack or decreased ac-
tivity of at least one lysosomal enzyme, 2) the stored
substance is normally degraded in lysosomes, and 3)
it is stored inside the lysosomes [2].
Cathepsin A (EC 3.4.16.1) prevents the processes
involved in lysosomal storage. Cathepsin A forms
complexes with glycosidases, protecting them in this
way against proteolytic inactivation [3, 4]. Decreased
lysosomal content of cathepsin A leads to the inacti-
vation of several glycosidases and accumulation of
glycosaminoglycans. Cathepsin C (EC 3.4.14.1) is also
involved in glycosaminoglycan metabolism. Cathep-
sin C releases the glycosidases from complexes formed
with cathepsin A, and reinstates their activity [5].
Cathepsin A
Cathepsin A is multifunctional lysosomal protein that
acts as a carboxypeptidase and forms complexes with
glycosidases at pH between 4.5 and 5.5; it exhibits
amidase and esterase activity at pH 7.0 [5, 6]. One
molecule of cathepsin A is composed of 438 amino
acid residues assembled into two subunits — cortical
and apical one with molecular masses of 32 kDa
(Ala1-Arg284) and 20 kDa (Met285-Tyr438), respec-
tively (Figure 1). The subunits are held together with
disulfide bonds C60-C361 and form a monomer of
cathepsin A [7]. Its catalytic site is built of Ser150,
Asp356, and His415 amino acid residues. Cathepsin A
monomer has a molecular mass of 52 kDa and mea-
sures 60 × 50 × 70 Å [8].
Under acidic pH, 60–70% of cathepsin A exists as
homodimers with 104 kDa molecular mass [6]. The
remaining 30–40% is present in the form of a two-
component, enzymatically active complex with beta-
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-galactosidase [7]. Its beta-galactosidase-binding con-
tact surface is formed of Gln76-Tyr84 and Val386-
-Glu391 sequences. Dimeric molecule of cathepsin A
binds to the monomer of beta-galactosidase (64 kDa)
forming a heterotrimer with 168 kDa molecular mass.
Four molecules of the heterotrimer form macrocom-
plex with 680 kDa molecular mass [6]. At pH 7.5, this
macrocomplex splits into 8 molecules of cathepsin A
and 4 molecules of beta-galactosidase [7, 9] (Figure 2).
Sodium dodecyl sulfate (SDS) dissociates this com-
plex into monomers that are further split into sub-
Figure 1. Amino acid sequence of cathepsin A: A1-R284 — 32 kDa subunit; M285-Y428 — 20kDa subunit; C — C
disulfide bond binding the subunits; S150-D356-H415 — catalytic triad; N17, N291 glycosylated rests; Q76-Y84,
V306-E401 — beta-galactosidase binding sequences [8]
Table 1. Amino acid composition of cathepsin A [44]
Amino acid* Cathepsin A Subunit
32 kDa 20 kDa
Ala (A) 23 14 9
Arg (R) 15 8 7
Asn (N) 33 22 11
Cys (C) 9 6 3
Phe (F) 20 14 6
Gln (Q) 26 15 11
Gly (G) 30 23 7
His (H) 8 6 2
Ile (I) 12 7 5
Asp (D) 22 15 7
Glu (E) 19 14 5
Leu (L) 51 35 16
Lys (K) 20 11 9
Met (M) 10 2 8
Pro (P) 25 16 9
Ser (S) 33 24 9
Thr (T) 21 11 10
Trp (W) 7 4 3
Tyr (Y) 27 18 9
Val (V) 27 19 8
Sum of amino acids 438 284 154
*Three-and one-letter code
Figure 2. Model of cathepsin A molecule monomer
[adopted from 9]. • – • – • — amino acids of catalytic triad
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Table 2. Glycosidases forming complexes with cathepsin A
Glycosidase Molecular mass Substrate Function Literature
kDa citation
Beta-D galactosidase (b-Gal) 64.0 Galactosaminoglycans Splits off galactose [30]
EC 3.2.1.23
Neuraminidase (Neu) 48.3 Sialoglycosaccharides Splits off neuraminic acid [13]
EC 3.2.1.18 (mucopolysaccharides)
6-N-galactosamine N-acetyl-6- 57.0 Glycosaminoglycans, keratan
-sulfate sulfatase (GALNS) sulfate, chondroitin 6-sulfate Splits off sulfate ion [43]
EC 3.1.6.4
units as a result of the addition of the reducing com-
pound. After reducing pH to 4.5, macrocomplex with
680 kDa molecular mass is formed again. The forma-
tion of this complex protects beta-galactosidase
against degradation and proteolytic inactivation [10,
11]. Complex of cathepsin A with beta-galactosidase
is isolated by means of affinity chromatography on
p-aminophenyl-beta-D-thiogalactopyranoside-agarose
[14]. Obtained complex of cathepsin A and beta-ga-
lactosidase is dissociated at pH 7.5 and fractioned into
its components by means of gel chromatography tech-
nique with Shim-pack Dial-3000 column. About 1%
of cathepsin A molecules is present as a polyenzy-
matic macrocomplex with beta-galactosidase,
N-acetyl-alpha-neuraminidase, and N-acetylgalac-
tosamine-6-sulfate sulfatase [12, 13]. This macrocom-
plex has a molecular mass of approximately 1280 kDa
[7, 14, 15]. Table 2 summarizes the characteristics of
glycosidases that are bound by cathepsin A.
Inherited deficiency or point mutations in the
amino acid sequence of cathepsin A (Q21R, S23Y,
W37R, S61L, V104M, L208P, Y221N, Y351C,
M365T, G389S, F398V) inhibit the formation of
dimeric forms and complexes with glycosidases [16–
–18]. Degradation and inactivation of beta-galactosi-
dase and neuraminidase are reflected by a second-
ary deficiency of those enzymes, leading to the ac-
cumulation of galactosaminoglycans and sialogly-
cosaccharides, and as a consequence to the storage
disease – mucopolysaccharidosis IV B and galacto-
sialidosis [19, 20]. Degradation of beta-galactosidase
is catalyzed by cysteine cathepsins [21]. Leupeptin,
an inhibitor of cathepsins, halts this process. De-
creased activity of cathepsin A can be observed in
the course of muscular dystrophy [22] and in multi-
ple sclerosis [23].
Cathepsin C
Cathepsin C also participates in the regulation of gly-
cosidase activity. It is a lysosomal cysteinyl peptidase
— an enzyme that cleaves off dipeptides from the
N-terminus of peptides and proteins [24, 25]. Moreover,
it hydrolyses dipeptide esters, amides, anilides, and
beta-naphtylamides [26]. Additionally, cathepsin C
shows the activity of transpeptidase [27]. It catalyzes
hydrolysis at pH 5.0–6.0 and transpeptidation at pH
6.8–7.0 [4]. Cathepsin C is activated by chloride an-
ions and sulfhydryl compounds [28].
One molecule of human cathepsin C is built of
206 amino acid residues, arranged in four polypep-
tide chains with a total molecular mass of approxi-
mately 200 kDa [29]. Its spatial model is presented in
Figure 4.
Figure 3. Macrocomplex of cathepsin A with beta-galactosi-
dase [according to 41]. At pH 7.5 the complex of cathepsin A
and beta-galactosidase (1) is dissociated into two cathepsin
homodimers (2) and beta-galactosidase 2a); sodium dodecyl
sulfate (SDS) dissociates homodimer of cathepsin A into
two monomers (3), while beta-mercaptoethanol /ß-Me/ splits
them further into 32 kDa (4) and 20 kDa subunits (5).
S-S — disulfide bonds binding subunits of the monomer;
= — hydrophobic bonds that bind the monomers
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The role of cathepsin C in the regulation of lysos-
omal enzymatic activity involves the release of beta-
-galactosidase and neuraminidase from complex with
cathepsin A (Figure 5). This process requires the pres-
ence of chloride anions (Cl–) and sulfhydryl com-
pounds [4, 30]. Released beta-galactosidase,
neuraminidase, and cathepsin A exhibit normal ac-
tivity. Genetic mutation and reduced activity of cathe-
psin C cause Papillon-Lefevre syndrome character-
ized by palmoplantar keratoderma, periodontitis, and
muscular dystrophy [3, 42].
Increased tissue activity of cathepsin A and cathe-
psin C can be observed in many pathological condi-
tions [24, 26, 31–34]. It is associated with an enhanced
degradation of glycosaminoglycans, proteoglycans,
and glycoproteins, and results in their decreased tis-
sue content [35–40].
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